Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous T-cell immunotherapy in advanced gastric cancer
NCT02704299Phase 1Unknown
- Sponsor
- AbelZeta
- Start
- Mar 2016
- Primary completion
- Jun 2018
- Modality
- CAR-T Cells, mRNA Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of RNA CART-meso in gastric cancer (GC), sponsored by AbelZeta. Primary endpoint: Progression-Free Survival at 24 months. Status: unknown.
02
Drugs
RNA CART-meso
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT02704299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02704299.